Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Mol Med Rep ; 15(4): 1441-1454, 2017 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-28259916

RESUMO

A subset of basal cell carcinomas (BCCs) are directly derived from hair follicles (HFs). In some respects, HFs can be defined as 'ordered' skin appendage growths, while BCCs can be regarded as 'disordered' skin appendage growths. The aim of the present study was to examine HFs and BCCs to define the expression of common and unique signaling pathways in each skin appendage. Human nodular BCCs, along with HFs and non­follicular skin epithelium from normal individuals, were examined using microarrays, qPCR, and immunohistochemistry. Subsequently, BCC cells and root sheath keratinocyte cells from HFs were cultured and treated with Notch signaling peptide Jagged1 (JAG1). Gene expression, protein levels, and cell apoptosis susceptibility were assessed using qPCR, immunoblotting, and flow cytometry, respectively. Specific molecular mechanisms were found to be involved in the process of cell self­renewal in the HFs and BCCs, including Notch and Hedgehog signaling pathways. However, several key Notch signaling factors showed significant differential expression in BCCs compared with HFs. Stimulating Notch signaling with JAG1 induced apoptosis of BCC cells by increasing Fas ligand expression and downstream caspase-8 activation. The present study showed that Notch signaling pathway activity is suppressed in BCCs, and is highly expressed in HFs. Elements of the Notch pathway could, therefore, represent targets for the treatment of BCCs and potentially in hair follicle engineering.


Assuntos
Apoptose , Carcinoma Basocelular/metabolismo , Carcinoma Basocelular/patologia , Receptores Notch/metabolismo , Transdução de Sinais , Neoplasias Cutâneas/metabolismo , Neoplasias Cutâneas/patologia , Apoptose/efeitos dos fármacos , Apoptose/genética , Carcinoma Basocelular/genética , Análise por Conglomerados , Proteína Ligante Fas/metabolismo , Perfilação da Expressão Gênica , Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos , Ontologia Genética , Redes Reguladoras de Genes/efeitos dos fármacos , Folículo Piloso/metabolismo , Folículo Piloso/patologia , Humanos , Proteína Jagged-1/farmacologia , Análise de Sequência com Séries de Oligonucleotídeos , Reprodutibilidade dos Testes , Transdução de Sinais/genética , Neoplasias Cutâneas/genética
2.
J Immunol ; 197(1): 377-86, 2016 07 01.
Artigo em Inglês | MEDLINE | ID: mdl-27233964

RESUMO

TNF-like cytokine 1A (TL1A) is expressed on APCs and provides costimulatory signals to activated lymphocytes that bear its functional receptor, death receptor 3 (DR3). TL1A/DR3 signaling is involved in the pathogenesis of human and experimental inflammatory bowel disease. In the current study, we investigated the role of this cytokine/receptor pair in acute intestinal injury/repair pathways. We demonstrate that intact DR3 signaling protected mice from acute dextran sodium sulfate colitis because DR3(-/-) mice showed more severe mucosal inflammation and increased mortality. DR3(-/-) mice were compromised in their ability to maintain adequate numbers of CD4(+)CD25(+)Foxp3(+) regulatory T cells in response to acute mucosal damage. This defect in immune regulation led to a nonspecific upregulation of effector proinflammatory pathways, which was most prominent for the Th17 immunophenotype. TL1A(-/-) mice were similarly more susceptible to dextran sodium sulfate colitis, although without mortality and with delayed kinetics compared with DR3(-/-) mice, and also displayed significantly reduced numbers of regulatory T cells. Infection of DR3(-/-) mice with Salmonella typhimurium was associated with defective microbial clearance and elevated bacterial load. Taken together, our findings indicate a novel protective role for the TL1A/DR3 axis in the regulation of mucosal homeostasis during acute intestinal injury/repair, which contrasts with its known pathogenic function during chronic intestinal inflammation.


Assuntos
Colite/imunologia , Intestinos/patologia , Membro 25 de Receptores de Fatores de Necrose Tumoral/metabolismo , Infecções por Salmonella/imunologia , Salmonella typhimurium/imunologia , Linfócitos T Reguladores/imunologia , Células Th17/imunologia , Membro 15 da Superfamília de Ligantes de Fatores de Necrose Tumoral/metabolismo , Animais , Células Cultivadas , Sulfato de Dextrana , Fatores de Transcrição Forkhead/metabolismo , Humanos , Intestinos/microbiologia , Camundongos , Camundongos Knockout , Camundongos SCID , Membro 25 de Receptores de Fatores de Necrose Tumoral/genética , Transdução de Sinais/genética , Membro 15 da Superfamília de Ligantes de Fatores de Necrose Tumoral/genética
3.
J Immunol Res ; 2015: 607328, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26000314

RESUMO

Immunosuppressive drugs successfully prevent rejection of islet allografts in the treatment of type I diabetes. However, the drugs also suppress systemic immunity increasing the risk of opportunistic infection and cancer development in allograft recipients. In this study, we investigated a new treatment for autoimmune diabetes using naturally immune privileged, hair follicle derived, autologous cells to provide localized immune protection of islet allotransplants. Islets from Balb/c mouse donors were cotransplanted with syngeneic hair follicle dermal sheath cup cells (DSCC, group 1) or fibroblasts (FB, group 2) under the kidney capsule of immune-competent, streptozotocin induced, diabetic C57BL/6 recipients. Group 1 allografts survived significantly longer than group 2 (32.2 ± 12.2 versus 14.1 ± 3.3 days, P < 0.001) without administration of any systemic immunosuppressive agents. DSCC reduced T cell activation in the renal lymph node, prevented graft infiltrates, modulated inflammatory chemokine and cytokine profiles, and preserved better beta cell function in the islet allografts, but no systemic immunosuppression was observed. In summary, DSCC prolong islet allograft survival without systemic immunosuppression by local modulation of alloimmune responses, enhancing of beta cell survival, and promoting of graft revascularization. This novel finding demonstrates the capacity of easily accessible hair follicle cells to be used as local immunosuppression agents in islet transplantation.


Assuntos
Aloenxertos/imunologia , Sobrevivência de Enxerto/imunologia , Folículo Piloso/citologia , Transplante das Ilhotas Pancreáticas/imunologia , Ilhotas Pancreáticas/citologia , Animais , Sobrevivência Celular/imunologia , Células Cultivadas , Diabetes Mellitus Experimental/imunologia , Diabetes Mellitus Experimental/cirurgia , Diabetes Mellitus Tipo 1/imunologia , Diabetes Mellitus Tipo 1/cirurgia , Feminino , Tolerância Imunológica/imunologia , Terapia de Imunossupressão , Ativação Linfocitária/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C3H , Camundongos Endogâmicos C57BL , Linfócitos T/imunologia
4.
PLoS One ; 9(5): e94260, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-24832234

RESUMO

Alopecia areata (AA) is a CD8+ T-cell dependent autoimmune disease of the hair follicle (HF) in which the collapse of HF immune privilege (IP) plays a key role. Mast cells (MCs) are crucial immunomodulatory cells implicated in the regulation of T cell-dependent immunity, IP, and hair growth. Therefore, we explored the role of MCs in AA pathogenesis, focusing on MC interactions with CD8+ T-cells in vivo, in both human and mouse skin with AA lesions. Quantitative (immuno-)histomorphometry revealed that the number, degranulation and proliferation of perifollicular MCs are significantly increased in human AA lesions compared to healthy or non-lesional control skin, most prominently in subacute AA. In AA patients, perifollicular MCs showed decreased TGFß1 and IL-10 but increased tryptase immunoreactivity, suggesting that MCs switch from an immuno-inhibitory to a pro-inflammatory phenotype. This concept was supported by a decreased number of IL-10+ and PD-L1+ MCs, while OX40L+, CD30L+, 4-1BBL+ or ICAM-1+ MCs were increased in AA. Lesional AA-HFs also displayed significantly more peri- and intrafollicular- CD8+ T-cells as well as more physical MC/CD8+ T-cell contacts than healthy or non-lesional human control skin. During the interaction with CD8+ T-cells, AA MCs prominently expressed MHC class I and OX40L, and sometimes 4-1BBL or ICAM-1, suggesting that MC may present autoantigens to CD8+ T-cells and/or co-stimulatory signals. Abnormal MC numbers, activities, and interactions with CD8+ T-cells were also seen in the grafted C3H/HeJ mouse model of AA and in a new humanized mouse model for AA. These phenomenological in vivo data suggest the novel AA pathobiology concept that perifollicular MCs are skewed towards pro-inflammatory activities that facilitate cross-talk with CD8+ T-cells in this disease, thus contributing to triggering HF-IP collapse in AA. If confirmed, MCs and their CD8+ T-cell interactions could become a promising new therapeutic target in the future management of AA.


Assuntos
Alopecia em Áreas/sangue , Alopecia em Áreas/imunologia , Linfócitos T CD8-Positivos/citologia , Mastócitos/citologia , Animais , Biópsia , Linfócitos T CD8-Positivos/imunologia , Proliferação de Células , Feminino , Folículo Piloso/patologia , Humanos , Inflamação , Interleucina-10/sangue , Mastócitos/imunologia , Camundongos , Camundongos Endogâmicos C3H , Pessoa de Meia-Idade , Fenótipo , Pele/metabolismo , Fator de Crescimento Transformador beta1/metabolismo
5.
J Am Acad Dermatol ; 62(2): 191-202, quiz 203-4, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20115946

RESUMO

UNLABELLED: Various therapeutic agents have been described for the treatment of alopecia areata (AA), but none are curative or preventive. The aim of AA treatment is to suppress the activity of the disease. The high rate of spontaneous remission and the paucity of randomized, double-blind, placebo-controlled studies make the evidence-based assessment of these therapies difficult. The second part of this two-part series on AA discusses treatment options in detail and suggests treatment plans according to specific disease presentation. It also reviews recently reported experimental treatment options and potential directions for future disease management. LEARNING OBJECTIVES: After completing this learning activity, participants should be able to compare the efficacy and safety of various treatment options, formulate a treatment plan tailored to individual patients, and recognize recently described treatments and potential therapeutic approaches.


Assuntos
Alopecia em Áreas/tratamento farmacológico , Administração Tópica , Corticosteroides/efeitos adversos , Adulto , Alopecia em Áreas/psicologia , Animais , Criança , Ciclopropanos/uso terapêutico , Ciclosporina/uso terapêutico , Cabelo/crescimento & desenvolvimento , Haptenos/uso terapêutico , Humanos , Imunoterapia , Injeções Intralesionais , Terapia a Laser , Metotrexato/uso terapêutico , Minoxidil/uso terapêutico , Fotoquimioterapia/efeitos adversos , Ensaios Clínicos Controlados Aleatórios como Assunto , Ratos , Recidiva , Projetos de Pesquisa , Apoio Social , Sulfassalazina/efeitos adversos , Resultado do Tratamento , Triancinolona Acetonida/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA